Canaccord Genuity reissued their buy rating on shares of Exact Sciences Corporation (NASDAQ:EXAS) in a research report report published on Tuesday morning. Canaccord Genuity currently has a $60.00 target price on the medical research company’s stock, up from their prior target price of $45.00.

Several other equities analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Exact Sciences Corporation from a buy rating to a hold rating in a report on Friday, August 4th. Vetr lowered Exact Sciences Corporation from a buy rating to a hold rating and set a $37.46 target price for the company. in a report on Wednesday, June 28th. Leerink Swann restated an outperform rating and set a $50.00 target price (up previously from $45.00) on shares of Exact Sciences Corporation in a report on Thursday, September 21st. Lake Street Capital increased their target price on Exact Sciences Corporation from $30.00 to $41.00 and gave the company a hold rating in a research report on Wednesday, July 26th. Finally, Bank of America Corporation reaffirmed a buy rating on shares of Exact Sciences Corporation in a research report on Wednesday, July 26th. Five analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Exact Sciences Corporation has a consensus rating of Buy and an average target price of $43.11.

Shares of Exact Sciences Corporation (NASDAQ:EXAS) traded down 3.28% during mid-day trading on Tuesday, hitting $47.51. The stock had a trading volume of 1,147,454 shares. The company’s 50 day moving average is $42.56 and its 200-day moving average is $34.76. Exact Sciences Corporation has a 52-week low of $13.05 and a 52-week high of $50.65. The stock’s market cap is $5.66 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.10. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. The business had revenue of $57.65 million for the quarter, compared to the consensus estimate of $47.73 million. On average, equities research analysts anticipate that Exact Sciences Corporation will post ($1.18) earnings per share for the current fiscal year.

WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/exact-sciences-corporations-exas-buy-rating-reaffirmed-at-canaccord-genuity/1608031.html.

In related news, insider Graham Peter Lidgard sold 45,775 shares of Exact Sciences Corporation stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $41.49, for a total value of $1,899,204.75. Following the completion of the sale, the insider now directly owns 288,952 shares in the company, valued at approximately $11,988,618.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP D Scott Coward sold 29,115 shares of Exact Sciences Corporation stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the completion of the sale, the senior vice president now owns 64,991 shares of the company’s stock, valued at $3,064,975.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 237,444 shares of company stock worth $10,412,421. Corporate insiders own 4.00% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Lord Abbett & CO. LLC increased its stake in Exact Sciences Corporation by 59.1% during the 2nd quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after purchasing an additional 875,527 shares in the last quarter. Krilogy Financial LLC raised its holdings in shares of Exact Sciences Corporation by 1,460.0% in the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after buying an additional 3,650 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Exact Sciences Corporation by 5.6% in the second quarter. Ameritas Investment Partners Inc. now owns 9,640 shares of the medical research company’s stock worth $341,000 after buying an additional 511 shares during the last quarter. Albion Financial Group UT purchased a new position in shares of Exact Sciences Corporation in the second quarter worth $211,000. Finally, Wafra Investment Advisory Group Inc. NY acquired a new stake in shares of Exact Sciences Corporation during the second quarter worth $4,863,000. Institutional investors and hedge funds own 85.23% of the company’s stock.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.